DMT — the most potent psychedelic drug known to man — treats people with serious illness depressed A cutting-edge clinical trial showed that after a single dose.
Six out of ten people who received a single dose of DMT intravenously before treatment were declared free of depression after three months.
Three in 10 participants declared depression-free two weeks after a course of treatment, compared with just one in 10 in the placebo group who received their own treatment.
N,N-Dymethyltriptamine (DMT) has celebrity endorsements such as Joe Rogan And it is gaining popularity as an alternative to stimulant antidepressants.
DMT is Ayahuasca’s natural hallucinogena strong beer widely used by tribal societies in the Amazon basin, where it was considered a “wisdom” plant that allowed access to the spirit world.
Ayahuasca is usually drunk as a beer during religious ceremonies, but in this study, participants received DMT through an IV drip for 10 minutes, which triggered a psychedelic experience for 20-30 minutes
These graphs show the percentage of responders at one and two weeks post-dose, as shown on the left, in Madras with a greater than or equal to 50% decline from baseline. For the group that received DMT, the remission rate was 44% after one week and 35% after two weeks. In the placebo group, the response rates were 6% and 12%, respectively. The right panel shows the response rate as determined by a MADRS score of 10 or less at one and two weeks. Remission rates were 44% and 29% in the DMT-treated group at one and two weeks, respectively, compared with 13% and 12% in the placebo group.Data Show Clinically Relevant Changes in Response and Remission Rates Following DMT Treatment
DMT and ayahuasca are part of the hallucinogen wave, along with psilocybin mushrooms and ketamine, which were once dismissed as hippie drugs but are now being explored by scientists as powerful therapeutics.
The latest study was conducted in 2021 by Canada-based biotech company Small Pharma.
It looked at 34 male and female participants with moderate or severe depression.
In the first part of the trial, 17 participants received 21.5 mg of DMT, about half the typical smoking dose.
They received the drug through an IV drip for 10 minutes, which triggered a 20-30 minute psychedelic experience, followed immediately by therapy to help them make sense of it.
The other 17 patients received treatment only.
Independent reviewers who did not know what treatment the participants were receiving rated how depressed people were using the Montgomery-Asberg Depression Scale (MADRS) at the start of the trial and then 1, 2 and 12 weeks later .
One week after dosing, the change in MADRS score was negative 10.8 in the DMT group compared to the placebo group.After two weeks, the group receiving DMT had a negative 7.4 difference in depression scores compared to the placebo group
After two weeks of treatment, the DMT group scored 7.4 points lower in depression than the placebo group, indicating a statistically significant reduction in depressive symptoms compared to the placebo group.
After three months of treatment, symptoms were further reduced—an overall mean reduction in the MADRS score of 15.4 points after one dose of DMT.
Six out of 10 people who received a single dose of DMT were also declared free of depression after three months.
This is defined as having a MADRS score of 10 or less.
Dr David Elizoi, a clinical psychiatrist at Imperial College London and lead researcher on the study, said: “These results are exciting for the psychiatric field. We now have the first evidence that DMT, when combined with supportive care, may Effective for people with MDD.
“For patients who are unfortunate enough to benefit little from existing antidepressants, the potential for rapid and durable relief from monotherapy, as shown in this trial, is very promising.”
So far, the therapeutic benefits of DMT have been mainly anecdotal, with evidence that The drug also carries a risk of long-term negative effects on mental health.
There are few scientific details about the exact effects of DMT on the brain, but studies have shown increased “availability” of monoamines in the amygdala, which increases the strength of memories.
Blood flow to the insula was also increased, which may account for users’ enhanced self-understanding.
This is thought to make therapy more effective because people can face their trauma with less fear.